Private company

Clarus Therapeutics (United States)

Clarus Therapeutics (United States) is an American biological products company based in Northbrook, founded in 2003.1

Last updated Oct 20, 2026.

Overview

2003Founded1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersNorthbrook1
  • Websitewww.clarustherapeutics.com
  • Incorporated inDE3
  • Business address355 S. Grand Avenue, Suite 1450, Los Angeles, Ca 900713
  • Filer category, Emerging growth company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Clarus Therapeutics (United States) image from its website
Image: clarustherapeutics.com4

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

80.5%Gross margin5
-291.0%Net margin5
119.1%Revenue growth, 20215
-$43.8MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Cost of revenue12¢$2.7M
  • Research and development16¢$3.6M
  • Interest71¢$15.9M

Out of $14.0M in revenue.5 The company lost money this year.

Financial statements

Revenue5$14.0M in 2021+119% since 2020
0$5.0M$10.0M$15.0M2020: $6.4M$6.4M20202021: $14.0M$14.0M2021+119%
Gross profit5$11.2M in 2021
-$5.0M0$5.0M$10.0M$15.0M2020: -$2.3M-$2.3M20202021: $11.2M$11.2M2021
Net income5-$40.6M in 2021
-$60.0M-$40.0M-$20.0M0$20.0M2020: $4.3M$4.3M20202021: -$40.6M-$40.6M2021
Fiscal year201920202021
Revenue$6.4M5$14.0M5
Cost of revenue$8.7M5$2.7M5
Gross profit-$2.3M5$11.2M5
Research and development$2.4M5$3.6M5
Operating expenses$51.0M5
Interest$15.4M5$15.9M5
Income before tax-$40.6M5
Income tax$05$05
Net income$4.3M5-$40.6M5
Earnings per share$0.005-$5.725
Earnings per share (diluted)-$8.205-$5.725
Shares (weighted, basic)7.0M shares5
Shares (weighted, diluted)7.0M shares5

Compare Clarus Therapeutics (United States) with another company

Corporate structure

Clarus Therapeutics (United States) sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Clarus Therapeutics (United States)

  • ARMISTICE CAPITAL, LLC Filed SC 13G/A on Clarus Therapeutics (United States), latest Feb 14, 2023 (2 filings since Feb 15, 2022)
  • Bracebridge Capital, LLC Filed SC 13G/A on Clarus Therapeutics (United States), latest Jul 6, 2022 (2 filings since Feb 14, 2022)
  • Thomas, McNerney & Partners, LLC Filed SC 13D/A on Clarus Therapeutics (United States), latest Apr 22, 2022 (2 filings since Dec 10, 2021)
  • Beryl Capital Management LLC Filed SC 13G/A on Clarus Therapeutics (United States), latest Feb 14, 2022
  • CVI Investments, Inc. Filed SC 13G/A on Clarus Therapeutics (United States), latest Feb 14, 2022
  • Lighthouse Investment Partners, LLC Filed SC 13G/A on Clarus Therapeutics (United States), latest Feb 14, 2022
  • Hudson Bay Capital Management LP Filed SC 13G/A on Clarus Therapeutics (United States), latest Feb 8, 2022
  • Weiss Asset Management LP Filed SC 13G/A on Clarus Therapeutics (United States), latest Feb 4, 2022
  • Karpus Management, Inc. Filed SC 13G/A on Clarus Therapeutics (United States), latest Oct 8, 2021
  • Clarus Therapeutics (United States) Northbrook

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Clarus Therapeutics (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$233.0K5 Dec 31, 2021$208.0K5 Dec 31, 2020+12.0%
Accumulated depreciation$168.0K5 Dec 31, 2021$144.0K5 Dec 31, 2020+16.7%
Property and equipment, net$65.0K5 Dec 31, 2021$64.0K5 Dec 31, 2020+1.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$26.4M5 Dec 31, 2021$7.2M5 Dec 31, 2020+265.2%

Inventory

ItemLatestA year beforeChange
Inventory, total$14.2M5 Dec 31, 2021$5.9M5 Dec 31, 2020+142.7%
Raw materials$6.8M5 Dec 31, 2021$4.2M5 Dec 31, 2020+62.1%

Leadership

Who has led Clarus Therapeutics (United States), and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Richard D. Peterson2021
20052010201520202025
Board members and other officers (9)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorRobert E. Dudley named Dec 21, 202118
  • DirectorJoseph Kenneth Hernandez named Dec 21, 202118

Former names

  • Blue Water Acquisition Corp.Jul 22, 2020 to Sep 9, 20213

Timeline

  1. Mar 1, 20238-K Bankruptcy or receivership; Completed an acquisition or sale; Change to shareholders' rights19
  2. Feb 22, 20238-K Regulation FD disclosure20
  3. Jan 24, 20238-K Regulation FD disclosure21
  4. Dec 22, 20228-K Regulation FD disclosure22
  5. Nov 23, 20228-K Regulation FD disclosure23
  6. Oct 31, 20228-K Entered a material agreement; Completed an acquisition or sale; Executive or director change24
  7. Oct 24, 20228-K Regulation FD disclosure25
  8. Oct 18, 20228-K Other events26
  9. Sep 15, 20228-K Change of auditor27
  10. Sep 6, 20228-K Bankruptcy or receivership; Executive or director change; Other events28
  11. Aug 26, 20228-K Listing notice or transfer29
  12. Aug 18, 20228-K Results of operations30
  13. 2003Founded Founded1

Calendar

When it reported results

  1. Aug 18, 2022Reported quarterly or annual results30
  2. May 16, 2022Reported quarterly or annual results31
  3. Mar 30, 2022Reported quarterly or annual results32
  4. Nov 18, 2021Reported quarterly or annual results33

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

142 filings to the SEC since October 2021: 2 annual reports, 3 quarterly reports, 25 major events, 19 insider forms, 12 large holders, 1 private raises, 80 other. The latest 20:

  1. Mar 6, 2023EFFECT EDGAR
  2. Mar 6, 2023EFFECT EDGAR
  3. Mar 6, 2023EFFECT EDGAR
  4. Mar 6, 2023EFFECT EDGAR
  5. Mar 1, 202315-12G EDGAR
  6. Mar 1, 20238-K CURRENT REPORT EDGAR
  7. Mar 1, 2023S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
  8. Mar 1, 2023POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 EDGAR
  9. Mar 1, 2023POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 EDGAR
  10. Mar 1, 2023POS AM POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 EDGAR
  11. Mar 1, 2023POS AM POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 EDGAR
  12. Feb 22, 20238-K CURRENT REPORT EDGAR
  13. Feb 14, 2023SC 13G/A EDGAR
  14. Jan 24, 20238-K CURRENT REPORT EDGAR
  15. Dec 22, 20228-K CURRENT REPORT EDGAR
  16. Nov 23, 20228-K CURRENT REPORT EDGAR
  17. Oct 31, 20228-K CURRENT REPORT EDGAR
  18. Oct 24, 20228-K CURRENT REPORT EDGAR
  19. Oct 18, 20228-K EDGAR
  20. Sep 15, 20228-K CURRENT REPORT EDGAR

The 142 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 0 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 20, 2022TMP Associates II LP10% ownerSale3,752,912$2.53$9.5MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Dec 7, 2021Raised $15 million in a private offering of equity Form D: 1 investor so far Form D

SEC filer profile

How Clarus Therapeutics (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARClarus Therapeutics Holdings, Inc.2
  • CIK0001817944
  • Employer ID (EIN)85-12318522
  • Filer status<br>emerging growth company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)2
  • Business address355 S. Grand Avenue, Suite 1450, Los Angeles, CA 900712
  • Phone(847) 562-43002
  • Shares outstanding52,020,731 as of Aug 17, 20227
  • Public float$25.6M as of Jun 30, 202143
  • On EDGAR sinceJul 22, 20202
  • Filings236 in all: 8-K (43), 424B3 (39), 4 (20), 3 (19), CORRESP (12), EFFECT (12), SC 13G (12), SC 13G/A (11)2
    All 36 form types

    425 (9), UPLOAD (8), POS AM (6), 10-Q (5), S-1 (5), NT 10-Q (3), S-1/A (3), 10-K (2), 10-K/A (2), 25-NSE (2), 4/A (2), 424B4 (2), DRS (2), S-4/A (2), SC 13D (2), 15-12G (1), 8-A12B (1), CERT (1), D (1), DEF 14A (1), NT 10-K (1), POS EX (1), PRE 14A (1), S-1MEF (1), S-4 (1), S-8 (1), S-8 POS (1), SC 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2022
    Quarterly report (10-Q) Aug 19, 2022
    Proxy statement (DEF 14A) May 9, 2022
    Latest 8-K (8-K) Mar 1, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
    SEC EDGAROther events
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43